Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu receptor negative allosteric modulator

  • Font Inglès, Joan|||0000-0001-8416-1909
  • López Cano, Marc|||0000-0001-8885-3726
  • Notartomaso, Serena|||0000-0003-4374-9233
  • Scarselli, Pamela|||0000-0002-4245-0849
  • Di Pietro, Paola|||0000-0003-1327-1961
  • Bresolí-Obach, Roger|||0000-0002-7819-7750
  • Battaglia, Giuseppe|||0000-0001-7571-3417
  • Malhaire, Fanny
  • Rovira, Xavier|||0000-0002-9764-9927
  • Catena, Juanlo|||0000-0002-2423-5926
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Goudet, Cyril|||0000-0002-8255-3535
  • Nonell, Santi|||0000-0002-8900-5291
  • Nicoletti, Ferdinando|||0000-0003-0917-443X
  • Llebaria, Amadeu|||0000-0002-8200-4827
  • Ciruela, Francisco|||0000-0003-0832-3739
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug's release, which effectively controls mGlu receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Photomodulation of G protein-coupled adenosine receptors by a novel light-switchable ligand

  • Bahamonde, María Isabel
  • Taura, Jaume
  • Paoletta, Silvia
  • Gakh, Anadrei A.
  • Chakraborty, Saibal
  • Hernando, Jordi|||0000-0002-1126-4138
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Ciruela, Francisco|||0000-0003-0832-3739
The adenosinergic system operates through G protein-coupled adenosine receptors, which have become promising therapeutic targets for a wide range of pathological conditions. However, the ubiquity of adenosine receptors and the eventual lack of selectivity of adenosine-based drugs have frequently diminished their therapeutic potential. Accordingly, here we aimed to develop a new generation of light-switchable adenosine receptor ligands that change their intrinsic activity upon irradiation, thus allowing the spatiotemporal control of receptor functioning (i.e., receptor activation/inactivation dependent on location and timing). Therefore, we synthesized an orthosteric, photoisomerizable, and nonselective adenosine receptor agonist, nucleoside derivative MRS5543 containing an aryl diazo linkage on the N substituent, which in the dark (relaxed isomer) behaved as a full adenosine A receptor (AR) and partial adenosine A receptor (AR) agonist. Conversely, upon photoisomerization with blue light (460 nm), it remained a full AR agonist but became an AR antagonist. Interestingly, molecular modeling suggested that structural differences encountered within the third extracellular loop of each receptor could modulate the intrinsic, receptor subtype-dependent, activity. Overall, the development of adenosine receptor ligands with photoswitchable activity expands the pharmacological toolbox in support of research and possibly opens new pharmacotherapeutic opportunities.